Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 573

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 573
---
-cash interest expense on liability recognized during the three and nine months ended September 30, 2023 as the Original HCR Agreement was entered into in the fourth quarter of 2023 (see “ — Royalty Purchase and Sale Agreement ” above). Comparison of the Years Ended December 31, 2023 and 2022 Revenue

| ​                          
 ​                          
 ​                          | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | 2023                        
 Dollar amounts in thousands 
 ​                           | ​ |      ​ | ​ | ​ | ​ | % change | ​ 
 ​ | ​ 
 ​ | 2022 
 ​    | ​ |      ​ | ​ | ​ | ​ | % change | ​ 
 ​ 
 ​ |
|:---------------------------|:--|:--|:----------------------------|:--|-------:|:--|:--|:--|:---------|:--|:--|:-----|:--|-------:|:--|:--|:--|:---------|:--|
| Collaborative revenue      | ​ | ​ | ​                           | $ | 12,936 | ​ | ​ | ​ | (22)%    | ​ | ​ | ​    | $ | 16,572 | ​ | ​ | ​ | 2,248%   | ​ |
| Commercial supply revenue  | ​ | ​ | ​                           | ​ |  5,843 | ​ | ​ | ​ | (43)%    | ​ | ​ | ​    | ​ | 10,223 | ​ | ​ | ​ | 1,358%   | ​ |
| License and milestone fees | ​ | ​ | ​                           | ​ |    910 | ​ | ​ | ​ | (94)%    | ​ | ​ | ​    | ​ | 15,000 | ​ | ​ | ​ | (29)%    | ​ |
| Royalty revenue            | ​ | ​ | ​                           | ​ |    415 | ​ | ​ | ​ | 476%     | ​ | ​ | ​    | ​ |     72 | ​ | ​ | ​ | N/A      | ​ |
| Clinical compound revenue  | ​ | ​ | ​                           | ​ |    165 | ​ | ​ | ​ | N/A      | ​ | ​ | ​    | ​ |      — | ​ | ​ | ​ | (100)%   | ​ |
| Other revenue              | ​ | ​ | ​                           | ​